PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1661631
PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1661631
The Global Neurovascular Thrombectomy Devices Market was estimated at 2.95 billion in 2024, and is projected to grow at a CAGR of 6.72% for the forecast period between 2025 and 2032. Increasing number of minimally invasive procedures, increasing incidence of stroke in patient population, technological breakthroughs, reimbursement policies, and rising healthcare expenditure by governments across emerging economies are some of the factors driving market expansion. Asia-Pacific nations such as China and India are predicted to emerge as new revenue-generating markets between 2025 and 2032.
Ongoing product developments by leading companies and key market players expanding their presence in emerging countries through the establishment of manufacturing facilities, research and development facilities, and distribution networks are expected to drive further growth of thrombectomy devices during the forecast period. As per reports published by WHO, neurovascular thrombectomy have shown improved patient outcomes post-surgery in developed and emerging countries, thrombectomy operations have grown rapidly in both established and emerging countries. The percentage of large vessel occlusion or LVO stroke patients undergoing thrombectomy treatments varies by country, however most of them stay below 15%.
Mergers and Acquisitions Support Market Expansion
Mergers and acquisitions are significant a driver for the global neurovascular thrombectomy devices market. They enable companies to expand their product portfolios by acquiring advanced technologies, thus catering to a wider range of medical needs. Mergers and acquisitions also facilitate entry into new geographic markets, increasing patient reach, and thus market share. Additionally, combining resources through mergers and acquisitions enhances research and development capabilities, leading to the innovation of more effective thrombectomy devices. Strategic partnerships formed through mergers and acquisitions improve supply chain efficiency and distribution networks, bolstering overall operational effectiveness.
For instance, in January 2025, Stryker Corporation announced a definitive agreement to acquire Inari Medical, Inc. This acquisition is expected to enhance Stryker's capabilities in treating vascular diseases, particularly in the context of thrombectomy procedures. This strategic move is allowing Stryker to broaden its product portfolio and address a wider range of vascular conditions, enhancing its market presence.
Stent Retriever is Dominating the Global Neurovascular Thrombectomy Devices Market
In 2022, the stent retrievers accounted for majority share the overall mechanical thrombectomy devices market, owing to increased reimbursement, increased public-private investments in product development & commercialization, and increased patient emphasis on minimally invasive therapeutic procedures.
North America is Expected to Hold a Significant Share during the Forecast Period
Over the projected period, North America is likely to have a sizable market share. The increasing frequency of acute ischemic strokes, increased research and development, regular product launches, and rising strategic initiatives by leading market players are the fundamental driving drivers for the North American neurovascular thrombectomy devices market.
Due to high frequency of stroke in the United States, the North American is expected to hold a substantial proportion of the market over the study period. According to the Centers for Disease Control and Prevention (CDC) report published in April 2022, more than 795,000 people in the United States experience a stroke each year and ischemic strokes account for approximately 87% of all reported strokes.
Impact of COVID-19 on the Global Neurovascular Thrombectomy Devices Market
COVID-19 has had a significant impact on the healthcare industry, including the neurovascular thrombectomy devices market. On one hand, there has been an increase in demand for these devices due to the higher incidence of stroke in COVID-19 patients. COVID-19 is known to cause blood clotting, which can increase the risk of stroke in patients. On the other hand, the pandemic disrupted supply chain and led to manufacturing and distribution challenges for neurovascular thrombectomy device manufacturers. Some manufacturers had to delay or halt production due to workforce shortages, supply chain disruptions, and other factors. This led to a shortage of neurovascular thrombectomy devices in some regions, which affected patient's access to these devices.
Impact of Russia-Ukraine War on the Global Neurovascular Thrombectomy Devices Market
The war between Russia and Ukraine had an indirect negative impact on the neurovascular thrombectomy market on a global scale. Geopolitical tensions and conflicts can have broader impacts on the global economy and neurovascular thrombectomy market due to trade disruptions, supply chain interruptions and economic sanctions imposed by United States and European countries on Russia.
Key Players Landscape and Outlook
Some of the leading companies in the Neurovascular Thrombectomy Devices market are Johnson & Johnson Medical Ltd, Medtronic Plc, Wallaby Medical Inc, Terumo Corp, Stryker Corp, Imperative Care Inc, Penumbra Inc, Balt SAS, and Acandis GmbH & Co KG. Medtronic Plc.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work